{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:52:05Z","timestamp":1772815925228,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ajem.2024.04.046","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T16:27:42Z","timestamp":1714494462000},"page":"227.e1-227.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["A case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"80","author":[{"given":"Sai-Ching Jim","family":"Yeung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiham","family":"Qdaisat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason J.","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey M.","family":"Caterino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrios N.","family":"Kyriacou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Coyne, MD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ajem.2024.04.046_bb0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with Cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.ajem.2024.04.046_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002121","article-title":"Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders","volume":"9","author":"Brown","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"36","key":"10.1016\/j.ajem.2024.04.046_bb0015","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajem.2024.04.046_bb0020","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). 1.2022","article-title":"Management of immunotherapy-related toxicities, version 1.2022","author":"Thompson","year":"2022"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.046_bb0025","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.046_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ajem.2024.04.046_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"On behalf of the ESMO guidelines committee. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow- up","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ajem.2024.04.046_bb0040","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s00432-019-03002-1","article-title":"C-reactive protein as an early marker of immune-related adverse events","volume":"145","author":"Abolhassani","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.046_bb0045","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00432-021-03550-5","article-title":"Inflammatory markers in autoimmunity induced by checkpoint inhibitors","volume":"147","author":"Husain","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.046_bb0050","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and Rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ajem.2024.04.046_bb0055","article-title":"Increased circulating levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer","volume":"12","author":"Yu","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.046_bb0060","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/CMR.0000000000000748","article-title":"C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting","volume":"31","author":"Lauwyck","year":"2021","journal-title":"Melanoma Res"},{"issue":"5","key":"10.1016\/j.ajem.2024.04.046_bb0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.21037\/atm-21-7006","article-title":"Immune checkpoint inhibitors and adrenal insufficiency: a large-sample case series study","volume":"10","author":"Cui","year":"2022","journal-title":"Ann Transl Med"},{"issue":"2","key":"10.1016\/j.ajem.2024.04.046_bb0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.annemergmed.2016.03.048","article-title":"Pituitary dysfunction: a case series of immune checkpoint inhibitor\u2013related hypophysitis in an emergency department","volume":"68","author":"Miller","year":"2016","journal-title":"Ann Emerg Med"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.046_bb0075","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.annemergmed.2018.08.421","article-title":"Addressing new diagnostic and treatment challenges associated with a new age of cancer treatment","volume":"73","author":"Bischof","year":"2019","journal-title":"Ann Emerg Med"},{"issue":"11","key":"10.1016\/j.ajem.2024.04.046_bb0080","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/ijc.34427","article-title":"The regulatory approvals of immune checkpoint inhibitors in China and the United States: a cross-national comparison study","volume":"152","author":"Jin","year":"2023","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ajem.2024.04.046_bb0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s44201-022-00002-9","article-title":"The current state of acute oncology training for emergency physicians: a narrative review","volume":"1","author":"Bischof","year":"2022","journal-title":"Emerg Cancer Care"},{"key":"10.1016\/j.ajem.2024.04.046_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jemermed.2023.02.016","article-title":"The 2022 Model of the clinical practice of emergency medicine","author":"Beeson","year":"2023","journal-title":"J Emerg Med"},{"issue":"4","key":"10.1016\/j.ajem.2024.04.046_bb0095","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","article-title":"Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians","volume":"55","author":"Hryniewicki","year":"2018","journal-title":"J Emerg Med"},{"key":"10.1016\/j.ajem.2024.04.046_bb0100","author":"NCCN"},{"issue":"10","key":"10.1016\/j.ajem.2024.04.046_bb0105","article-title":"The most recent oncologic emergency: what emergency physicians need to know about the potential complications of immune checkpoint inhibitors","volume":"9","author":"Simmons","year":"2017","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.ajem.2024.04.046_bb0110","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/emp2.12209","article-title":"Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department","volume":"1","author":"Yeung","year":"2020","journal-title":"J Am Coll Emerg Physicians Open"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675724002043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675724002043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T07:59:20Z","timestamp":1716883160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675724002043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":22,"alternative-id":["S0735675724002043"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2024.04.046","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A case series of adrenal insufficiency (likely due to hypophysitis) in cancer patients treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2024.04.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}